Baylor College of Medicine: New Drug Potentially Identified To Expand Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment
September 23, 2022
September 23, 2022
HOUSTON, Texas, Sept. 23 (TNSjou) -- The Baylor College of Medicine issued the following news:
The therapeutic drug pirfenidone has been found to be a potential treatment for rheumatoid arthritis-associated interstitial lung disease by researchers at Baylor College of Medicine, National Jewish Health and sites around the world.
This complication of rheumatoid arthritis affects 7.7% of people diagnosed with the autoimmune disease that affects nearly 1% of the entire pop . . .
The therapeutic drug pirfenidone has been found to be a potential treatment for rheumatoid arthritis-associated interstitial lung disease by researchers at Baylor College of Medicine, National Jewish Health and sites around the world.
This complication of rheumatoid arthritis affects 7.7% of people diagnosed with the autoimmune disease that affects nearly 1% of the entire pop . . .